MX2012008212A - Uso de un agente modificador de hormonas suprarrenales. - Google Patents
Uso de un agente modificador de hormonas suprarrenales.Info
- Publication number
- MX2012008212A MX2012008212A MX2012008212A MX2012008212A MX2012008212A MX 2012008212 A MX2012008212 A MX 2012008212A MX 2012008212 A MX2012008212 A MX 2012008212A MX 2012008212 A MX2012008212 A MX 2012008212A MX 2012008212 A MX2012008212 A MX 2012008212A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- hydrogen
- aryl
- modifying agent
- halogen
- Prior art date
Links
- 230000001919 adrenal effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002438 stress hormone Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento de una enfermedad o trastorno caracterizado por un aumento en los niveles de hormonas de estrés y/o por una disminución en los niveles de hormonas de andrógenos en un sujeto, el cual comprende administrar al sujeto, una cantidad terapéuticamente efectiva de un compuesto representado por la fórmula (I): (Ver Formula) en donde n es 1 ó 3; R es hidrógeno o --C(O)N(Ra)-(Rb), en donde Ra y Rb son independientemente --alquilo (de 1 a 4 átomos de carbono), o --alquilo (de 1 a 4 átomos de carbono)-arilo (de 5 a 7 átomos de carbono), en donde cada uno de Ra y Rb está opcionalmente sustituido por --alcoxilo (de 1 a 4 átomos de carbono); R1, R2, y R3, son independientemente hidrógeno, halógeno, ciano o --arilo (de 6 a 10 átomos de carbono), en donde este --arilo (de 6 a 10 átomos de carbono) está opcionalmente sustituido por halógeno, con la condición de que no más de uno de R1, R2, y R3 es hidrógeno; y R4 y R5 son hidrógeno; o de una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29498010P | 2010-01-14 | 2010-01-14 | |
| PCT/US2011/021100 WO2011088188A1 (en) | 2010-01-14 | 2011-01-13 | Use of an adrenal hormone-modifying agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012008212A true MX2012008212A (es) | 2012-08-03 |
Family
ID=43735742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011700A MX354022B (es) | 2010-01-14 | 2011-01-13 | Uso de un agente modificador de hormonas suprarrenales. |
| MX2012008212A MX2012008212A (es) | 2010-01-14 | 2011-01-13 | Uso de un agente modificador de hormonas suprarrenales. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011700A MX354022B (es) | 2010-01-14 | 2011-01-13 | Uso de un agente modificador de hormonas suprarrenales. |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8609862B2 (es) |
| EP (2) | EP2523731B1 (es) |
| JP (4) | JP5602250B2 (es) |
| KR (1) | KR101412206B1 (es) |
| CN (2) | CN105440038A (es) |
| AU (1) | AU2011205290C1 (es) |
| BR (1) | BR112012017458B1 (es) |
| CA (1) | CA2786443C (es) |
| CL (1) | CL2012001961A1 (es) |
| CY (2) | CY1121320T1 (es) |
| DK (1) | DK2523731T3 (es) |
| ES (1) | ES2707596T3 (es) |
| HR (1) | HRP20190064T1 (es) |
| HU (2) | HUE041967T2 (es) |
| IL (1) | IL220804A0 (es) |
| LT (2) | LT2523731T (es) |
| LU (1) | LUC00159I2 (es) |
| MA (1) | MA33904B1 (es) |
| ME (1) | ME03371B (es) |
| MX (2) | MX354022B (es) |
| NL (1) | NL301043I2 (es) |
| NO (1) | NO2020012I1 (es) |
| NZ (1) | NZ601077A (es) |
| PH (1) | PH12012501422B1 (es) |
| PL (1) | PL2523731T3 (es) |
| PT (1) | PT2523731T (es) |
| RS (1) | RS58234B1 (es) |
| RU (1) | RU2598708C2 (es) |
| SG (1) | SG182393A1 (es) |
| SI (1) | SI2523731T1 (es) |
| TN (1) | TN2012000352A1 (es) |
| TR (1) | TR201900515T4 (es) |
| WO (1) | WO2011088188A1 (es) |
| ZA (1) | ZA201205058B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190064T1 (hr) * | 2010-01-14 | 2019-03-08 | Novartis Ag | Uporaba sredstva za modifikaciju adrenalnog hormona |
| KR20130135820A (ko) | 2010-06-16 | 2013-12-11 | 엠베라 뉴로 테라퓨틱스 인코포레이티드 | 중독，정신 장애 및 신경퇴행성 질환 치료용 조성물 및 방법 |
| TWI518073B (zh) | 2011-06-14 | 2016-01-21 | 美國禮來大藥廠 | 醛固酮合成酶抑制劑 |
| WO2013043520A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| US9351973B2 (en) | 2011-09-22 | 2016-05-31 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| PE20142358A1 (es) * | 2012-01-17 | 2015-01-30 | Novartis Ag | Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa |
| IN2014DN09240A (es) | 2012-04-12 | 2015-07-10 | Novartis Ag | |
| CA2886117C (en) | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
| JP2015093832A (ja) * | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
| MX2016017315A (es) * | 2014-07-07 | 2017-04-27 | Novartis Ag | Formas de dosificacion farmaceutica. |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| AU2016210899B2 (en) * | 2015-01-29 | 2019-03-07 | Recordati Ag | Process for the production of condensed imidazolo Derivatives |
| US20160287565A1 (en) | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| CA2990413A1 (en) * | 2015-06-22 | 2016-12-29 | Embera Neurotherapeutics, Inc. | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders |
| AU2018230521B2 (en) | 2017-03-10 | 2022-02-03 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4814333A (en) | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5503843A (en) | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| US5658881A (en) | 1994-10-14 | 1997-08-19 | Twk, Inc. | Method for topical inhibition of the metabolic activity of cytochrome P450 |
| DE19814087A1 (de) * | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
| US7417038B1 (en) | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
| ES2275853T3 (es) | 2001-02-16 | 2007-06-16 | Aventis Pharmaceuticals Inc. | Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3. |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| JP5138875B2 (ja) | 2005-07-19 | 2013-02-06 | 株式会社デンソー | センサ装置 |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| CA2645678A1 (en) | 2006-03-16 | 2007-09-20 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| US20100240641A1 (en) * | 2006-05-26 | 2010-09-23 | Julien Papillon | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| AU2007290695A1 (en) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| EP2121652A1 (en) * | 2006-12-18 | 2009-11-25 | Novartis AG | 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |
| EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| HRP20190064T1 (hr) * | 2010-01-14 | 2019-03-08 | Novartis Ag | Uporaba sredstva za modifikaciju adrenalnog hormona |
| PE20142358A1 (es) * | 2012-01-17 | 2015-01-30 | Novartis Ag | Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa |
| IN2014DN09240A (es) * | 2012-04-12 | 2015-07-10 | Novartis Ag |
-
2011
- 2011-01-13 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 RU RU2012134510/15A patent/RU2598708C2/ru active
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 PH PH1/2012/501422A patent/PH12012501422B1/en unknown
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en not_active Ceased
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Active
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
-
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
-
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
-
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
-
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
-
2019
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
-
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012008212A (es) | Uso de un agente modificador de hormonas suprarrenales. | |
| MX347616B (es) | Inhibidores de csf-1r para el tratamiento de tumores de cerebro. | |
| JP2012144574A5 (es) | ||
| EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
| GB201103103D0 (en) | Organic compounds | |
| IN2014CN00794A (es) | ||
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| PH12013500848B1 (en) | Trpv1 antagonists and uses thereof | |
| WO2009073148A3 (en) | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| PH12017501294A1 (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| WO2012141796A3 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| EA200970512A1 (ru) | Лечение по поводу множественной миеломы | |
| IN2014DN05869A (es) | ||
| PH12015501560A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| WO2014130409A3 (en) | Fungicidal pyrazole mixtures | |
| MX2016005383A (es) | Composiciones para tratar formaciones subterraneas. | |
| RU2011137324A (ru) | Лиганды рецепторов эстрогенов и способы их применения | |
| WO2012107735A3 (en) | Treatment of bipolar disorder | |
| TW200744575A (en) | Methods of treating epileptogenesis | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| WO2013175359A3 (en) | Compositions and methods for the treatment of multiple sclerosis | |
| EA201070819A1 (ru) | Соединения n-фенилимидазо[1,2-a]пиридин-2-карбоксамида, их получение и их применени в терапии | |
| PH12012501476A1 (en) | Aminoquinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |